Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
About
Home
NICE guidance
Awaiting development
Guidance and quality standards
Awaiting development
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter (3 active)
Skip to results
Filter by title or keyword
Filter
Area of interest
Area of interest
COVID-19 (8)
Type
(
1 selected
)
Type
Guidance (288)
Guidance programme
(
2 selected
)
Guidance programme
Diagnostics guidance (2)
Health technology evaluations (2)
Highly specialised technologies guidance (1)
Interventional procedures guidance (18)
Medical technologies guidance (7)
Technology appraisal guidance (287)
Apply filters
Showing 11 to 20 of 288
Type: Guidance
Remove Type: Guidance filter
Guidance programme: Technology appraisal guidance
Remove Guidance programme: Technology appraisal guidance filter
Guidance programme: Highly specialised technologies guidance
Remove Guidance programme: Highly specialised technologies guidance filter
Guidance and quality standards awaiting development
Title
Type
Afamitresgene autoleucel for previously treated MAGE-A4 positive advanced synovial sarcoma or myxoid round cell liposarcoma [ID4064]
Technology appraisal guidance
Alpelisib for treating severe PIK3CA-related overgrowth spectrum in people 2 years and over TS ID 10680
Technology appraisal guidance
Alpelisib with olaparib for treating BRCA wild-type platinum-refractory or -resistant ovarian, fallopian tube or primary peritoneal cancer after 1 to 3 previous treatments TS ID 11830
Technology appraisal guidance
Andexanet alfa for reversing anticoagulation in people with intracranial haemorrhage (part review of TA697) [ID6335]
Technology appraisal guidance
Apadamtase alfa for preventing and treating congenital thrombotic thrombocytopenic purpura caused by ADAMTS-13 deficiency [ID6192]
Technology appraisal guidance
Apalutamide with radical prostatectomy for untreated high-risk, localised or locally advanced prostate cancer TS ID 11967
Technology appraisal guidance
Atezolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for early triple negative breast cancer ID 6200
Technology appraisal guidance
Atezolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID3894]
Technology appraisal guidance
Atezolizumab for adjuvant treatment of high-risk locally advanced squamous cell head and neck cancer [ID4052]
Technology appraisal guidance
Atezolizumab with cabozantinib for treating hormone-relapsed metastatic prostate cancer after 1 therapy [ID6203]
Technology appraisal guidance
Previous page
1
Current page
2
3
4
…
29
Page
2
of
29
Next page
Results per page
10
25
50
All
Back to top